Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-28T03:18:18.936Z Has data issue: false hasContentIssue false
  • English
  • Français

The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory

Published online by Cambridge University Press:  24 April 2020

Alejandro Ballesteros ,
Ana M. Sánchez Torres Open the ORCID record for Ana M. Sánchez Torres [Opens in a new window] ,
Jose López-Ilundáin ,
Gisela Mezquida ,
Antonio Lobo Open the ORCID record for Antonio Lobo [Opens in a new window] ,
Ana González-Pinto Open the ORCID record for Ana González-Pinto [Opens in a new window] ,
Laura Pina-Camacho Open the ORCID record for Laura Pina-Camacho [Opens in a new window] ,
Iluminada Corripio Open the ORCID record for Iluminada Corripio [Opens in a new window] ,
Eduard Vieta Open the ORCID record for Eduard Vieta [Opens in a new window]  and
Elena de la Serna Open the ORCID record for Elena de la Serna [Opens in a new window]
...Show all authors
Alejandro Ballesteros
Affiliation:
Red de Salud Mental de Navarra, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain Instituto de Investigación Sanitaria de Navarra (IdiSNa), Pamplona, Spain
Ana M. Sánchez Torres
Affiliation:
Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain Instituto de Investigación Sanitaria de Navarra (IdiSNa), Pamplona, Spain
Jose López-Ilundáin
Affiliation:
Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain Instituto de Investigación Sanitaria de Navarra (IdiSNa), Pamplona, Spain
Gisela Mezquida
Affiliation:
Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), August Pi I Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain
Antonio Lobo
Affiliation:
Department of Medicine and Psychiatry, Zaragoza University, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
Ana González-Pinto
Affiliation:
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain BIOARABA Health Research Institute, OSI Araba, University Hospital, University of the Basque Country, Vitoria, Spain
Laura Pina-Camacho
Affiliation:
Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM, CIBERSAM, Madrid, Spain
Iluminada Corripio
Affiliation:
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain Psychiatry Department, Institut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Eduard Vieta
Affiliation:
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain Unidad de Trastornos bipolares y depresivos, Hospital Clínic, Universidad de Barcelona, IDIBAPS, Barcelona, Spain
Elena de la Serna
Affiliation:
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain Department of Child and Adolescent Psychiatry and Psychology, Clínic Institute of Neurosciences, Hospital Clínic de Barcelona, 2017SGR881, Spain
Anna Mané
Affiliation:
Hospital del Mar Medical Research Institute (IMIM), CIBERSAM, Autonomous University of Barcelona, Barcelona, Spain
Miquel Bioque
Affiliation:
Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), August Pi I Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain
Lucía Moreno-Izco
Affiliation:
Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain Instituto de Investigación Sanitaria de Navarra (IdiSNa), Pamplona, Spain
Ana Espliego
Affiliation:
Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM, CIBERSAM, Madrid, Spain
Ruth Lorente-Omeñaca
Affiliation:
Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain Instituto de Investigación Sanitaria de Navarra (IdiSNa), Pamplona, Spain
Silvia Amoretti
Affiliation:
Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), August Pi I Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain
Miguel Bernardo
Affiliation:
Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), August Pi I Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain
Manuel J. Cuesta*
Affiliation:
Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain Instituto de Investigación Sanitaria de Navarra (IdiSNa), Pamplona, Spain
*
Author for correspondence: Manuel J. Cuesta, E-mail: mcuestaz@navarra.es
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Previous literature supports antipsychotics’ (AP) efficacy in acute first-episode psychosis (FEP) in terms of symptomatology and functioning but also a cognitive detrimental effect. However, regarding functional recovery in stabilised patients, these effects are not clear. Therefore, the main aim of this study is to investigate dopaminergic/anticholinergic burden of (AP) on psychosocial functioning in FEP. We also examined whether cognitive impairment may mediate these effects on functioning.

Methods

A total of 157 FEP participants were assessed at study entry, and at 2 months and 2 years after remission of the acute episode. The primary outcomes were social functioning as measured by the functioning assessment short test (FAST). Cognitive domains were assessed as potential mediators. Dopaminergic and anticholinergic AP burden on 2-year psychosocial functioning [measured with chlorpromazine (CPZ) and drug burden index] were independent variables. Secondary outcomes were clinical and socio-demographic variables.

Results

Mediation analysis found a statistical but not meaningful contribution of dopaminergic receptor blockade burden to worse functioning mediated by cognition (for every 600 CPZ equivalent points, 2-year FAST score increased 1.38 points). Regarding verbal memory and attention, there was an indirect effect of CPZ burden on FAST (b = 0.0045, 95% CI 0.0011–0.0091) and (b = 0.0026, 95% CI 0.0001–0.0006) respectively. However, only verbal memory post hoc analyses showed a significant indirect effect (b = 0.009, 95% CI 0.033–0.0151) adding premorbid IQ as covariate. We did not find significant results for anticholinergic burden.

Conclusion

CPZ dose effect over functioning is mediated by verbal memory but this association appears barely relevant.

Keywords

Antipsychoticscognitiondopaminergic receptor blockade burdenfirst episode psychosisfunctioning
Type
Original Article
Information
Psychological Medicine , Volume 51 , Issue 12 , September 2021 , pp. 2044 - 2053
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alvarez-Jimenez, M., O'Donoghue, B., Thompson, A., Gleeson, J. F., Bendall, S., Gonzalez-Blanch, C., … McGorry, P. D. (2016). Beyond clinical remission in first episode psychosis: Thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era. CNS Drugs, 30(5), 357–368. https://doi.org/10.1007/s40263-016-0331-x.CrossRefGoogle Scholar
American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Association.Google Scholar
Amoretti, S., Bernardo, M., Bonnin, C. M., Bioque, M., Cabrera, B., Mezquida, G., … Torrent, C. (2016). The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 26(10), 1638–1648. https://doi.org/10.1016/j.euroneuro.2016.07.003.CrossRefGoogle ScholarPubMed
Amoretti, S., Cabrera, B., Torrent, C., Mezquida, G., Lobo, A., González-Pinto, A., … PEPsGroup. (2018). Cognitive reserve as an outcome predictor: First-episode affective versus non-affective psychosis. Acta Psychiatrica Scandinavica, 138(5), 441–455. https://doi.org/10.1111/acps.12949.CrossRefGoogle ScholarPubMed
Andreasen, N. C., Liu, D., Ziebell, S., Vora, A., & Ho, B.-C. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: A prospective longitudinal MRI study. The American Journal of Psychiatry, 170(6), 609–615. https://doi.org/10.1176/appi.ajp.2013.12050674.CrossRefGoogle ScholarPubMed
Ang, M. S., Abdul Rashid, N. A., Lam, M., Rapisarda, A., Kraus, M., Keefe, R. S. E., & Lee, J. (2017). The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. Journal of Clinical Psychopharmacology, 37(6), 651–656. https://doi.org/10.1097/JCP.0000000000000790.CrossRefGoogle ScholarPubMed
Ballesteros, A., Sánchez-Torres, A. M., López-Ilundain, J. M., Cabrera, B., Lobo, A., González-Pinto, A. M., … PEPs Group. (2018). Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis? Psychological Medicine, 48(13), 2247–2256. https://doi.org/10.1017/S0033291717003774.CrossRefGoogle ScholarPubMed
Bernardo, M., Bioque, M., Parellada, M., Saiz Ruiz, J., Cuesta, M. J., Llerena, A., … PEPs Group. (2013). Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). Revista De Psiquiatria Y Salud Mental, 6(1), 4–16. https://doi.org/10.1016/j.rpsm.2012.11.001.CrossRefGoogle Scholar
Bolin, J. H. (2014). Hayes, andrew F. (2013). Introduction to mediation, moderation, and conditional process analysis: A regression-based approach. New York, NY: The Guilford press: Book review. Journal of Educational Measurement, 51(3), 335–337. https://doi.org/10.1111/jedm.12050.CrossRefGoogle Scholar
Carpenter, W. T., Appelbaum, P. S., & Levine, R. J. (2003). The declaration of Helsinki and clinical trials: A focus on placebo-controlled trials in schizophrenia. The American Journal of Psychiatry, 160(2), 356–362. https://doi.org/10.1176/appi.ajp.160.2.356.CrossRefGoogle Scholar
Cassidy, C. M., Rabinovitch, M., Schmitz, N., Joober, R., & Malla, A. (2010). A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. Journal of Clinical Psychopharmacology, 30(1), 64–67. https://doi.org/10.1097/JCP.0b013e3181ca03df.CrossRefGoogle ScholarPubMed
Chang, W. C., Ming Hui, C. L., Yan Wong, G. H., Wa Chan, S. K., Ming Lee, E. H., & Hai Chen, E. Y. (2013). Symptomatic remission and cognitive impairment in first-episode schizophrenia: A prospective 3-year follow-up study. The Journal of Clinical Psychiatry, 74(11), e1046–e1053. https://doi.org/10.4088/JCP.13m08355.CrossRefGoogle ScholarPubMed
Chiliza, B., Asmal, L., Kilian, S., Phahladira, L., & Emsley, R. (2015). Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia. Human Psychopharmacology, 30(3), 173–182. https://doi.org/10.1002/hup.2469.CrossRefGoogle ScholarPubMed
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018). What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry: Official Journal of the World Psychiatric Association (WPA), 17(2), 149–160. https://doi.org/10.1002/wps.20516.CrossRefGoogle ScholarPubMed
Cuesta, M. J., Sánchez-Torres, A. M., Cabrera, B., Bioque, M., Merchán-Naranjo, J., Corripio, I., … PEPs Group. (2015). Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. Schizophrenia Research, 164(1–3), 65–73. https://doi.org/10.1016/j.schres.2015.02.022.CrossRefGoogle ScholarPubMed
Deckersbach, T., Nierenberg, A. A., McInnis, M. G., Salcedo, S., Bernstein, E. E., Kemp, D. E., … Kamali, M. (2016). Baseline disability and poor functioning in bipolar disorder predict worse outcomes: Results from the Bipolar CHOICE study. The Journal of Clinical Psychiatry, 77(1), 100–108. https://doi.org/10.4088/JCP.14m09210.CrossRefGoogle ScholarPubMed
Drimer, T., Shahal, B., & Barak, Y. (2004). Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. International Clinical Psychopharmacology, 19(1), 27–29.CrossRefGoogle ScholarPubMed
Faber, G., Smid, H. G. O. M., Van Gool, A. R., Wiersma, D., & Van Den Bosch, R. J. (2012). The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. European Psychiatry: The Journal of the Association of European Psychiatrists, 27(4), 275–280. https://doi.org/10.1016/j.eurpsy.2011.02.003.CrossRefGoogle ScholarPubMed
Fusar-Poli, P., Byrne, M., Valmaggia, L., Day, F., Tabraham, P., Johns, L., … Team, O. A. S. I. S. (2010). Social dysfunction predicts two years clinical outcome in people at ultra high risk for psychosis. Journal of Psychiatric Research, 44(5), 294–301. https://doi.org/10.1016/j.jpsychires.2009.08.016.CrossRefGoogle ScholarPubMed
Galderisi, S., Mucci, A., Bitter, I., Libiger, J., Bucci, P., Fleischhacker, W. W., … Eufest Study Group. (2013). Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 23(3), 196–204. https://doi.org/10.1016/j.euroneuro.2012.04.019.CrossRefGoogle ScholarPubMed
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010). International consensus study of antipsychotic dosing. The American Journal of Psychiatry, 167(6), 686–693. https://doi.org/10.1176/appi.ajp.2009.09060802.CrossRefGoogle ScholarPubMed
González-Blanch, C., Pérez-Iglesias, R., Rodríguez-Sánchez, J. M., Pardo-García, G., Martínez-García, O., Vázquez-Barquero, J. L., & Crespo-Facorro, B. (2011). A digit symbol coding task as a screening instrument for cognitive impairment in first-episode psychosis. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists, 26(1), 48–58. https://doi.org/10.1093/arclin/acq086.CrossRefGoogle ScholarPubMed
Green, M. F., & Nuechterlein, K. H. (2004). The MATRICS initiative: Developing a consensus cognitive battery for clinical trials. Schizophrenia Research, 72(1), 1–3. https://doi.org/10.1016/j.schres.2004.09.006.CrossRefGoogle Scholar
Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., … Marder, S. R. (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry, 56(5), 301–307. https://doi.org/10.1016/j.biopsych.2004.06.023.CrossRefGoogle ScholarPubMed
Grove, W. M., & Andreasen, N. C. (1982). Simultaneous tests of many hypotheses in exploratory research. The Journal of Nervous and Mental Disease, 170(1), 3–8.CrossRefGoogle ScholarPubMed
Gunnmo, P., & Bergman, H. F. (2011). What do individuals with schizophrenia need to increase their well-being. International Journal of Qualitative Studies on Health and Well-Being, 6(1). https://doi.org/10.3402/qhw.v6i1.5412.CrossRefGoogle ScholarPubMed
Harrow, M., Jobe, T. H., Faull, R. N., & Yang, J. (2017). A 20-year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Research, 256, 267–274. https://doi.org/10.1016/j.psychres.2017.06.069.CrossRefGoogle Scholar
Harvey, P. D., & Keefe, R. S. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. The American Journal of Psychiatry, 158(2), 176–184. https://doi.org/10.1176/appi.ajp.158.2.176.CrossRefGoogle ScholarPubMed
Hayes, A. F. (2018). Introduction to mediation, moderation, and conditional process analysis: A regression-based approach (2nd ed.). New York: Guilford Press.Google Scholar
Jordan, G., Lutgens, D., Joober, R., Lepage, M., Iyer, S. N., & Malla, A. (2014). The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. The Journal of Clinical Psychiatry, 75(6), e566–e572. https://doi.org/10.4088/JCP.13m08606.CrossRefGoogle ScholarPubMed
Kahn, R. S., & Keefe, R. S. E. (2013). Schizophrenia is a cognitive illness: Time for a change in focus. JAMA Psychiatry, 70(10), 1107–1112. https://doi.org/10.1001/jamapsychiatry.2013.155.CrossRefGoogle ScholarPubMed
Kane, J. M., Leucht, S., Carpenter, D., Docherty, J. P., & Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. (2003). The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. The Journal of Clinical Psychiatry, 64 (Suppl 12), 5–19.Google ScholarPubMed
Karson, C., Duffy, R. A., Eramo, A., Nylander, A.-G., & Offord, S. J. (2016). Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: A systematic review. Neuropsychiatric Disease and Treatment, 12, 57–67. https://doi.org/10.2147/NDT.S96392.CrossRefGoogle ScholarPubMed
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.CrossRefGoogle Scholar
Landolt, K., Rössler, W., Ajdacic-Gross, V., Derks, E. M., Libiger, J., Kahn, R. S., … EUFEST Study Group. (2016). Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST). Schizophrenia Research, 172(1–3), 145–151. https://doi.org/10.1016/j.schres.2016.01.046.CrossRefGoogle Scholar
Leucht, S., Winter-van Rossum, I., Heres, S., Arango, C., Fleischhacker, W. W., Glenthøj, B., … Sommer, I. E. (2015). The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: Rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophrenia Bulletin, 41(3), 549–558. https://doi.org/10.1093/schbul/sbv019.CrossRefGoogle Scholar
Mackinnon, D. P. (2011). Integrating mediators and moderators in research design. Research on Social Work Practice, 21(6), 675–681. https://doi.org/10.1177/1049731511414148.CrossRefGoogle ScholarPubMed
Mayoral-van Son, J., de la Foz, V. O.-G., Martinez-Garcia, O., Moreno, T., Parrilla-Escobar, M., Valdizan, E. M., & Crespo-Facorro, B. (2016). Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: A 3-year naturalistic follow-up study. The Journal of Clinical Psychiatry, 77(4), 492–500. https://doi.org/10.4088/JCP.14m09540.CrossRefGoogle ScholarPubMed
Moncrieff, J. (2006). Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica, 114(1), 3–13. https://doi.org/10.1111/j.1600-0447.2006.00787.x.CrossRefGoogle ScholarPubMed
Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., … Taylor, D. (2016). Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? The British Journal of Psychiatry: The Journal of Mental Science, 209(5), 361–365. https://doi.org/10.1192/bjp.bp.116.182683.CrossRefGoogle ScholarPubMed
O'Donoghue, B., Francey, S. M., Nelson, B., Ratheesh, A., Allott, K., Graham, J., … McGorry, P. (2018). Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. Early Intervention in Psychiatry, 13(4), 953–960. https://doi.org/10.1111/eip.12716.CrossRefGoogle Scholar
Ogino, S., Miyamoto, S., Miyake, N., & Yamaguchi, N. (2014). Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. Psychiatry and Clinical Neurosciences, 68(1), 37–49. https://doi.org/10.1111/pcn.12088.CrossRefGoogle ScholarPubMed
Omachi, Y., & Sumiyoshi, T. (2018). Dose reduction/discontinuation of antipsychotic drugs in psychosis; effect on cognition and functional outcomes. Frontiers in Psychiatry, 9, 447. https://doi.org/10.3389/fpsyt.2018.00447.CrossRefGoogle ScholarPubMed
O'Reilly, K., O'Connell, P., Donohoe, G., Coyle, C., O'Sullivan, D., Azvee, Z., … Kennedy, H. G. (2016). Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: A 3-year prospective cohort study. Psychological Medicine, 46(15), 3199–3211. https://doi.org/10.1017/S0033291716002154.CrossRefGoogle ScholarPubMed
Peralta, V., & Cuesta, M. J. (1994). Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Research, 53(1), 31–40.CrossRefGoogle Scholar
Petri, H., & Urquhart, J. (1991). Channeling bias in the interpretation of drug effects. Statistics in Medicine, 10(4), 577–581. https://doi.org/10.1002/sim.4780100409.CrossRefGoogle ScholarPubMed
Read, J., & Williams, J. (2019). Positive and negative effects of antipsychotic medication: An international online survey of 832 recipients. Current Drug Safety, 14(3), 173–181. https://doi.org/10.2174/1574886314666190301152734.CrossRefGoogle ScholarPubMed
Rice, M. E., & Harris, G. T. (2005). Comparing effect sizes in follow-up studies: ROC Area, Cohen's d, and r. Law and Human Behavior, 29(5), 615–620. https://doi.org/10.1007/s10979-005-6832-7.CrossRefGoogle Scholar
Rosa, A. R., Sánchez-Moreno, J., Martínez-Aran, A., Salamero, M., Torrent, C., Reinares, M., … Vieta, E. (2007). Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clinical Practice and Epidemiology in Mental Health: CP & EMH, 3, 5. https://doi.org/10.1186/1745-0179-3-5.CrossRefGoogle Scholar
Salimi, K., Jarskog, L. F., & Lieberman, J. A. (2009). Antipsychotic drugs for first-episode schizophrenia: A comparative review. CNS Drugs, 23(10), 837–855. https://doi.org/10.2165/11314280-000000000-00000.CrossRefGoogle ScholarPubMed
Strålin, P., Skott, M., & Cullberg, J. (2018). Early recovery and employment outcome 13 years after first episode psychosis. Psychiatry Research, 271, 374–380. https://doi.org/10.1016/j.psychres.2018.12.013.CrossRefGoogle ScholarPubMed
Suvisaari, J., Mantere, O., Keinänen, J., Mäntylä, T., Rikandi, E., Lindgren, M., … Raij, T. T. (2018). Is it possible to predict the future in first-episode psychosis? Frontiers in Psychiatry, 9, 580. https://doi.org/10.3389/fpsyt.2018.00580.CrossRefGoogle Scholar
Swartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., … CATIE Investigators. (2007). Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE study. The American Journal of Psychiatry, 164(3), 428–436. https://doi.org/10.1176/ajp.2007.164.3.428.CrossRefGoogle ScholarPubMed
Taylor, M., Cavanagh, J., Hodgson, R., & Tiihonen, J. (2012). Examining the effectiveness of antipsychotic medication in first-episode psychosis. Journal of Psychopharmacology (Oxford, England), 26(Suppl 5), 27–32. https://doi.org/10.1177/0269881112439252.CrossRefGoogle ScholarPubMed
Thompson, A., Winsper, C., Marwaha, S., Haynes, J., Alvarez-Jimenez, M., Hetrick, S., … Sullivan, S. A. (2018). Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: Systematic review. BJPsych Open, 4(4), 215–225. https://doi.org/10.1192/bjo.2018.17.CrossRefGoogle ScholarPubMed
Viguera, A. C., Baldessarini, R. J., Hegarty, J. D., van Kammen, D. P., & Tohen, M. (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry, 54(1), 49–55. https://doi.org/10.1001/archpsyc.1997.01830130055011.CrossRefGoogle ScholarPubMed
Weller, A., Gleeson, J., Alvarez-Jimenez, M., McGorry, P., Nelson, B., Allott, K., … Killackey, E. (2018). Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol. Early Intervention in Psychiatry. 13(6):1345-1356. https://doi.org/10.1111/eip.12769.Google ScholarPubMed
Welsh, T. J., van der Wardt, V., Ojo, G., Gordon, A. L., & Gladman, J. R. F. (2018). Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: A systematic review of reviews. Drugs & Aging. 35(6):523-538. https://doi.org/10.1007/s40266-018-0549-z.CrossRefGoogle ScholarPubMed
Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry, 70(9), 913–920. https://doi.org/10.1001/jamapsychiatry.2013.19.CrossRefGoogle ScholarPubMed
Zou, X., Zhu, Y., Jackson, J. W., Bellavia, A., Fitzmaurice, G. M., Centorrino, F., & Valeri, L. (2018). The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning: A causal mediation analysis approach. NPJ Schizophrenia, 4(1), 13. https://doi.org/10.1038/s41537-018-0054-8.CrossRefGoogle ScholarPubMed
Supplementary material: File

Ballesteros et al. supplementary material

Tables S1-S9

Download Ballesteros et al. supplementary material(File)
File 36.5 KB